IE
CTXR icon

Israel Englander’s Citius Pharmaceuticals CTXR Stock Holding History

Israel Englander’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,320
Closed -$129K – 5951
2024
Q4 		$129K Sell
32,320
-14,020
-30% -$94.4K ﹤0.01% 5428
2024
Q3 		$580K Sell
46,340
-35,614
-43% -$599K ﹤0.01% 4710
2024
Q2 		$1.2M Buy
+81,954
New +$1.47M ﹤0.01% 3973
2023
Q3 		– Sell
-2,507
Closed -$75.2K – 6194
2023
Q2 		$75.2K Sell
2,507
-9,672
-79% -$318K ﹤0.01% 5393
2023
Q1 		$356K Sell
12,179
-9,866
-45% -$284K ﹤0.01% 4803
2022
Q4 		$435K Sell
22,045
-9,346
-30% -$255K ﹤0.01% 4840
2022
Q3 		$950K Sell
31,391
-38,218
-55% -$1.05M ﹤0.01% 4384
2022
Q2 		$1.6M Buy
+69,609
New +$1.91M ﹤0.01% 3926
2021
Q2 		– Sell
-6,725
Closed -$299K – 6608
2021
Q1 		$299K Buy
6,725
+6,323
+1,573% +$252K ﹤0.01% 5213
2020
Q4 		$10K Buy
+402
New +$10.5K ﹤0.01% 5144
2017
Q4 		– Sell
-799
Closed -$63K – 3829
2017
Q3 		$63K Buy
+799
New +$62.3K ﹤0.01% 3390

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCA
Bay Colony Advisors Concord, Massachusetts $903M AUM 33.67% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Israel Englander's CTXR Position: Q1 2025 in Review

Israel Englander sold out of Citius Pharmaceuticals (CTXR) in Q1 2025, closing a stake of 32,320 shares — an estimated $129K sold.

Israel Englander first reported a position in CTXR in Q3 2017 and held it in 11 quarters. The position peaked at $1.6M in Q2 2022. 28 funds tracked by Wall St. Rank hold CTXR as of Q1 2025.

  • Israel Englander reported no remaining Citius Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Israel Englander sold 32,320 Citius Pharmaceuticals shares in Q1 2025, an estimated $129K.
  • Israel Englander first reported a position in Citius Pharmaceuticals in Q3 2017 and held it in 11 quarters.
  • Israel Englander's Citius Pharmaceuticals position peaked at $1.6M in Q2 2022.
  • 28 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.